Juho Joutsa Selected Research

2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropane

1/2022	Diagnostic value of micrographia in Parkinson's disease: a study with [123I]FP-CIT SPECT.
11/2021	Diagnostic accuracy of glabellar tap sign for Parkinson's disease.
1/2021	Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials.
9/2019	Burden of non-motor symptoms in unclear parkinsonism and tremor: A study with [123I]FP-CIT SPECT.
9/2019	Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism.
4/2019	Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.
11/2016	Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.
3/2016	Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging.
4/2015	Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease.
10/2014	Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juho Joutsa Research Topics

Disease

20	Parkinson Disease (Parkinson's Disease) 10/2022 - 01/2012
8	Parkinsonian Disorders (Parkinsonism) 01/2021 - 07/2015
6	Gambling (Pathological Gambling) 01/2020 - 05/2012
5	Epilepsy (Aura) 10/2022 - 01/2015
5	Tremor (Tremors) 12/2019 - 10/2014
4	Essential Tremor (Essential Tremors) 10/2022 - 01/2021
4	Cognitive Dysfunction 01/2022 - 01/2015
4	Binge-Eating Disorder (Binge Eating Disorder) 01/2020 - 04/2017
3	Alzheimer Disease (Alzheimer's Disease) 11/2017 - 01/2015
3	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2013 - 05/2012
2	Dystonia (Limb Dystonia) 10/2022 - 01/2019
2	Mental Disorders (Mental Disorder) 10/2022 - 12/2017
2	Brain Diseases (Brain Disorder) 10/2022 - 10/2020
1	Torticollis (Wryneck) 04/2021
1	Secondary Parkinson Disease (Secondary Parkinsonism) 01/2021
1	Dyskinesias (Dyskinesia) 01/2021
1	Multiple Sclerosis 11/2019
1	Autoimmune Diseases (Autoimmune Disease) 11/2019
1	Chronic Progressive Multiple Sclerosis 11/2019
1	Hypokinesia (Bradykinesia) 09/2019
1	Dementia (Dementias) 01/2018
1	Obesity 01/2018
1	Morbid Obesity 01/2018
1	Feeding and Eating Disorders (Eating Disorder) 01/2018
1	Substance-Related Disorders (Drug Abuse) 04/2017
1	Bulimia (Binge Eating) 04/2017
1	Tinnitus 01/2017
1	Disease Progression 08/2016
1	Paraparesis 03/2016
1	Neuroinflammatory Diseases 03/2015
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2015
1	Neuroleptic Malignant Syndrome 09/2014
1	Food Addiction 05/2012
1	Neoplasm Metastasis (Metastasis) 04/2010
1	Neoplasms (Cancer) 04/2010
1	Squamous Cell Carcinoma of Head and Neck 04/2010

Drug/Important Bio-Agent (IBA)

18	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 05/2012
13	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2022 - 09/2014
10	2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA 01/2022 - 10/2014
6	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 01/2012
4	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2020 - 04/2015
4	Amyloid (Amyloid Fibrils)IBA 01/2018 - 01/2015
3	Neurotransmitter Agents (Neurotransmitter)IBA 10/2022 - 04/2017
3	LigandsIBA 10/2022 - 07/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2017
3	Opioid Analgesics (Opioids)IBA 01/2018 - 04/2017
2	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 11/2017
2	carfentanil (carfentanyl)IBA 01/2020 - 01/2018
2	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2020 - 01/2018
2	fluorodopa F 18IBA 05/2012 - 01/2012
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 10/2019
1	Bupropion (Wellbutrin)FDA LinkGeneric 09/2019
1	A-factor (Streptomyces)IBA 04/2019
1	Serotonin (5 Hydroxytryptamine)IBA 12/2017
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2017
1	CarbonIBA 01/2017
1	Apolipoproteins E (ApoE)IBA 01/2017
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	HomocysteineIBA 08/2016
1	Whey ProteinsIBA 08/2016
1	Nitrous Oxide (Laughing Gas)IBA 03/2016
1	Proteins (Proteins, Gene)FDA Link 03/2015
1	(18F)FEMPAIBA 03/2015
1	brassIBA 10/2014
1	Dopamine Agents (Dopaminergic Agents)IBA 09/2014
1	Dopamine Agonists (Dopamine Agonist)IBA 12/2012
1	RacloprideIBA 05/2012
1	Selegiline (E250)FDA LinkGeneric 01/2012
1	Cabergoline FDA LinkGeneric 01/2012
1	Metalloproteases (Metalloproteinases)IBA 04/2010
1	ThrombospondinsIBA 04/2010
1	DisintegrinsIBA 04/2010
1	Matrix Metalloproteinases (MMPs)IBA 04/2010
1	Tissue Inhibitor of MetalloproteinasesIBA 04/2010
1	Peptide Hydrolases (Proteases)FDA Link 04/2010

Therapy/Procedure

6	Deep Brain Stimulation 10/2022 - 01/2018
3	Therapeutics 01/2021 - 01/2012
2	Transcranial Magnetic Stimulation 10/2020 - 01/2017
1	Transcranial Direct Current Stimulation 10/2020
1	Drug Therapy (Chemotherapy) 01/2015
1	Vagus Nerve Stimulation 01/2015